Peter Radovich Sells 2,382 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06. Following the completion of the sale, the chief operating officer directly owned 20,679 shares of the company’s stock, valued at approximately $1,929,971.07. The trade was a 10.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $94.29 on Friday. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $96.84. The company has a market cap of $4.85 billion, a price-to-earnings ratio of -109.64 and a beta of 0.48. The company’s fifty day moving average price is $77.33 and its two-hundred day moving average price is $70.78. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. The firm’s revenue for the quarter was up 47.1% on a year-over-year basis. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the business. MCF Advisors LLC boosted its holdings in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals in the third quarter worth about $33,000. Comerica Bank raised its position in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the period. Quarry LP purchased a new position in Mirum Pharmaceuticals in the third quarter valued at about $41,000. Finally, CWM LLC grew its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on MIRM shares. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. Citizens Jmp raised their price objective on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Evercore ISI reaffirmed an “outperform” rating and set a $101.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, HC Wainwright reissued a “buy” rating and set a $102.00 price target (up from $81.00) on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.58.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.